Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds

therapy response

  • The Prognostic Value of Posttreatment <sup>68</sup>Ga-PSMA-11 PET/CT and <sup>18</sup>F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with <sup>177</sup>Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN)
    You have access
    The Prognostic Value of Posttreatment 68Ga-PSMA-11 PET/CT and 18F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with 177Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN)
    Sarennya Pathmanandavel, Megan Crumbaker, Andrew Nguyen, Andrew O. Yam, Peter Wilson, Remy Niman, Maria Ayers, Shikha Sharma, Peter Eu, Andrew J. Martin, Martin R. Stockler, Anthony M. Joshua and Louise Emmett
    Journal of Nuclear Medicine January 1, 2023, 64 (1) 69-74; DOI: https://doi.org/10.2967/jnumed.122.264104
  • mCRPC Patients Receiving <sup>225</sup>Ac-PSMA-617 Therapy in the Post–Androgen Deprivation Therapy Setting: Response to Treatment and Survival Analysis
    Open Access
    mCRPC Patients Receiving 225Ac-PSMA-617 Therapy in the Post–Androgen Deprivation Therapy Setting: Response to Treatment and Survival Analysis
    Mike Sathekge, Frank Bruchertseifer, Mariza Vorster, Ismaheel O. Lawal, Otto Knoesen, Johncy Mahapane, Cindy Davis, Amanda Mdlophane, Alex Maes, Kgomotso Mokoala, Kgomotso Mathabe, Christophe Van, de Wiele and Alfred Morgenstern
    Journal of Nuclear Medicine October 1, 2022, 63 (10) 1496-1502; DOI: https://doi.org/10.2967/jnumed.121.263618
  • Imaging Calreticulin for Early Detection of Immunogenic Cell Death During Anticancer Treatment
    You have access
    Imaging Calreticulin for Early Detection of Immunogenic Cell Death During Anticancer Treatment
    Dong-Yeon Kim, Ayoung Pyo, Misun Yun, Ramar Thangam, Sung-Hwan You, Ying Zhang, Ye-rim Jung, Dinh-Huy Nguyen, Akhil Venu, Hyeon Sik Kim, Mee Sun Yoon, Yeongjin Hong and Jung-Joon Min
    Journal of Nuclear Medicine July 1, 2021, 62 (7) 956-960; DOI: https://doi.org/10.2967/jnumed.120.245290
  • You have access
    TERT Promoter Mutation Predicts Radioiodine-Refractory Character in Distant Metastatic Differentiated Thyroid Cancer
    Xue Yang, Jiao Li, Xiaoyi Li, Zhiyong Liang, Wen Gao, Jun Liang, Shujun Cheng and Yansong Lin
    Journal of Nuclear Medicine February 1, 2017, 58 (2) 258-265; DOI: https://doi.org/10.2967/jnumed.116.180240
  • You have access
    Does PET SUV Harmonization Affect PERCIST Response Classification?
    Elske Quak, Pierre-Yves Le Roux, Charline Lasnon, Philippe Robin, Michael S. Hofman, David Bourhis, Jason Callahan, David S. Binns, Cédric Desmonts, Pierre-Yves Salaun, Rodney J. Hicks and Nicolas Aide
    Journal of Nuclear Medicine November 1, 2016, 57 (11) 1699-1706; DOI: https://doi.org/10.2967/jnumed.115.171983
  • You have access
    Monitoring Therapy Response of Experimental Arthritis with Radiolabeled Tracers Targeting Fibroblasts, Macrophages, or Integrin αvβ3
    Samantha Y.A. Terry, Marije I. Koenders, Gerben M. Franssen, Tapan K. Nayak, Anne Freimoser-Grundschober, Christian Klein, Wim J. Oyen, Otto C. Boerman and Peter Laverman
    Journal of Nuclear Medicine March 1, 2016, 57 (3) 467-472; DOI: https://doi.org/10.2967/jnumed.115.162628
  • You have access
    Postchemotherapy and Tumor-Selective Targeting with the La-Specific DAB4 Monoclonal Antibody Relates to Apoptotic Cell Clearance
    Fares Al-Ejeh, Alexander H. Staudacher, Douglas R. Smyth, Jocelyn M. Darby, Delphine Denoyer, Chris Tsopelas, Rodney J. Hicks and Michael P. Brown
    Journal of Nuclear Medicine May 1, 2014, 55 (5) 772-779; DOI: https://doi.org/10.2967/jnumed.113.130559
  • You have access
    Early Assessment of Tumor Response to Gefitinib Treatment by Noninvasive Optical Imaging of Tumor Vascular Endothelial Growth Factor Expression in Animal Models
    Zhaofei Liu, Xianlei Sun, Hao Liu, Teng Ma, Jiyun Shi, Bing Jia, Huiyun Zhao and Fan Wang
    Journal of Nuclear Medicine May 1, 2014, 55 (5) 818-823; DOI: https://doi.org/10.2967/jnumed.113.133660
  • You have access
    18F-Alfatide II and 18F-FDG Dual-Tracer Dynamic PET for Parametric, Early Prediction of Tumor Response to Therapy
    Jinxia Guo, Ning Guo, Lixin Lang, Dale O. Kiesewetter, Qingguo Xie, Quanzheng Li, Henry S. Eden, Gang Niu and Xiaoyuan Chen
    Journal of Nuclear Medicine January 1, 2014, 55 (1) 154-160; DOI: https://doi.org/10.2967/jnumed.113.122069
SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire